斑秃是一种以斑块状脱发为特征的自身免疫性疾病，这种脱发通常发生在头皮上，但也会影响眉毛、睫毛、面部毛发和身体的其他部位。斑秃患者的症状由免疫细胞攻击健康毛囊引起，导致头发脱落。斑秃平均发病年龄在25至35岁之间，但也可影响老年人、儿童和青少年，无明显性别差异。斑秃严重影响患者健康和生活质量，可能引起严重心理障碍，包括抑郁和焦虑。据估计，美国约有680万人患有斑秃，全球约有1.47亿人患有斑秃。 利 ...

Sustained scalp, eyebrow, and eyelash hair regrowth among patients with alopecia areata may be achieved with continuous, long-term ritlecitinib in patients who did and did not achieve early clinical ...

The growing comprehension of the pathogenesis of celiac disease has paved the way for the exploration of alternative treatment strategies. These novel approaches are aimed at addressing the condition ...

The growing comprehension of the pathogenesis of celiac disease has paved the way for the exploration of alternative treatment strategies. These novel approaches are aimed at addressing the ...

Treatments for hair regrowth include medicated formulas, supplements, lasers, and complementary remedies, such as massage and ...

There are approx. 25+ key companies which are developing the therapies for Cutaneous T-cell lymphoma. The companies which have their Cutaneous T-cell lymphoma drug candidates in the most advanced ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Given as a once-daily tablet, Litfulo (ritlecitinib) has been recommended by cost-effectiveness agency NICE for use in people aged 12 and over. The decision comes a few months after the first drug ...

A focused evaluation of scalp hair should be part of every newborn physical assessment. Although typically completed in the delivery room, it may be useful to re-evaluate the infant after the ...

Background: Flutamide has been rarely used for the treatment of female pattern hair loss (FPHL). Flutamide treatment for FPHL has not been evaluated in long-term studies with sufficiently large ...